Neobe

Neobe Therapeutics is a synthetic biology company that designs programmable, live biotherapeutics to act as microbial trojan horses for cancer treatment. Its platform engineers safe, tumor-colonizing bacterial strains to disrupt the highly fibrotic stroma of solid tumors. By locally releasing agents that remodel the tumor microenvironment, these engineered bacteria break down physical barriers that prevent immune cell infiltration, aiming to enable the success of immunotherapies in patients with immune-excluded tumors who currently do not respond to conventional treatments.

This technology addresses a critical challenge in oncology, where dense tumor microenvironments prevent drugs and immune cells from reaching their targets. By focusing on safe and localized remodeling, Neobe seeks to significantly expand the patient population eligible for immunotherapy. The company, founded in 2021 by experts in tumor microenvironment and bacterial engineering, is currently advancing two proprietary products in preclinical development. Neobe has secured backing from investors including Pioneer Group, 2048 Ventures, Deep Science Ventures, and Cancer Research Horizons to support its mission of transforming cancer treatment.